| Authors: |
Myers AA; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Briganti A; Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Leibovich B; Department of Urology, Mayo Clinic, Rochester, MN, USA., Lerner SP; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Moschini M; Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Rouprêt M; Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Spiess PE; Department of GU Oncology and Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA., Stenzl A; Department of Urology, Eberhard Karls University of Tübingen, Tübingen, Germany., Taneja SS; Department of Urology, NYU Langone Health, New York, NY, USA., Touijer KA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: AKamat@mdanderson.org. |
